Biological age moves in the right direction when the underlying system is supported. Labs-led where the data is available — foundation, metabolic, cognitive, hormonal — and conservative about what gets prescribed, and when.
Longevity here is not a shelf of supplements promising more years. It is supervised, lab-informed work on the systems that age — metabolic, hormonal, cognitive, mitochondrial — built from the foundation up rather than the headline down.
Where labs are available, they lead. We would rather replete a deficiency you actually have than load a compound you've read about. The order matters: get the foundation full, characterize the system, then layer interventions on top of behavior — sleep, training, energy balance — never instead of it.
And we are conservative about what gets prescribed, and when. The strength of the evidence sets the posture. Some of this branch is well established. Some is honestly contested, and we say which is which.
Energy and recovery are real benefits patients report. Lifespan is not a claim we make.
NAD declines with age — that much is uncontested — and precursors raise it. Patients commonly report better energy and recovery. Hormonal and metabolic markers respond to supervised work. These are benefits worth pursuing, and we frame them as what they are.
That NAD, or most of this category, extends human life is unproven and, in places, disputed — and the loudest proponents often hold the deepest commercial conflicts. Zashel makes no lifespan claim. We prescribe for healthspan and for how you feel, not for years no one can honestly promise.
Each layer is lab-gated where labs are available and clinician-prescribed where a prescription is required. You opt in to the layers your picture calls for; the clinician confirms what's appropriate.
The universal entry. Replete what's low before treating anything else — a deficiency left in place will quietly undermine everything layered on top of it.
Dysregulated cortisol is a shared driver across both sexes. We characterize the pattern first, then support it — and time the support to the curve rather than dosing blind.
Insulin sensitivity is among the highest-leverage longevity markers. The evidence here is unusually good and unusually contested at once; we lead with the stronger-evidenced agents and are candid about the weaker case for the rest.
Support for cellular energy and recovery — framed as support, not enhancement. Doses here are deliberately conservative, kept below the ranges where the evidence thins and the risk rises.
Lab-led hormone optimization for men and women — the single largest gap in most longevity offerings, and one we treat directly rather than refer out. Bioidentical only, screened carefully, and timed to the window where benefit and safety are greatest.
Peptides for recovery, tissue, and the growth-hormone axis — prescribed only where they can be reliably and legally compounded. The category moves with the regulatory landscape; we name only what we can actually prescribe today.
The advanced layer is individualized and gated on genuine clinician judgment — not a default, and not for everyone. It is offered where the clinical picture supports it and the prescribing clinician is comfortable, with monitoring built in.
We treat it in-house, lab-led, bioidentical, and screened — for men and women alike.
Hormone optimization begins with a full panel, not a symptom. For men whose labs justify it, the options range from testosterone-supportive approaches that preserve fertility to testosterone itself, in the delivery form you choose once the clinician lays out the trade-offs.
Estrogen is managed, not crushed — it matters for the male brain, bone, and vasculature. And for the man whose labs don't justify treatment, the honest answer is upstream first: sleep, body composition, cortisol.
Bioidentical hormone therapy where it's indicated — estradiol, progesterone, and low-dose testosterone — alongside perimenopause recognition and thyroid screening. Bioidentical only, and timed to the window where the benefit and the safety case are strongest.
Vasomotor symptoms are treated as a real biomarker of change, not a nuisance to endure. Where the picture is complex or out of window, the clinician routes to specialist care rather than forcing a fit.
The epigenetic clocks are an interesting way to track yourself over time. They are not a verdict. We offer them as an exploratory measure — not validated against lifespan in trials, and never the basis of a prescription.An optional add-on, framed honestly
Leave an email and we will write to you — once — when the assessment opens.
Thank you. You are on the list. We will write when the practice opens.